Danielli, Riccardo <br/><br/>
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy.  [electronic resource] 

 -  Expert opinion on biological therapy  07 2018 
 - 77-83 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1744-7682 
<br/><br/><label>Standard No.: </label>10.1080/14712598.2018.1494717  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents, Immunological--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>CTLA-4 Antigen--antagonists & inhibitors<br/>Cell Cycle Checkpoints--drug effects<br/>Clinical Trials, Phase II as Topic<br/>Dacarbazine--administration & dosage<br/>Drug Synergism<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Ipilimumab--administration & dosage<br/>Male<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Protein Kinase Inhibitors--administration & dosage<br/>Randomized Controlled Trials as Topic<br/>Skin Neoplasms--drug therapy<br/>Survival Analysis<br/>Thymalfasin--administration & dosage<br/>Time Factors<br/>Young Adult